Role of TNF-α in vascular dysfunction

Healthy vascular function is primarily regulated by several factors including EDRF (endothelium-dependent relaxing factor), EDCF (endothelium-dependent contracting factor) and EDHF (endothelium-dependent hyperpolarizing factor). Vascular dysfunction or injury induced by aging, smoking, inflammation, trauma, hyperlipidaemia and hyperglycaemia are among a myriad of risk factors that may contribute to the pathogenesis of many cardiovascular diseases, such as hypertension, diabetes and atherosclerosis. However, the exact mechanisms underlying the impaired vascular activity remain unresolved and there is no current scientific consensus. Accumulating evidence suggests that the inflammatory cytokine TNF (tumour necrosis factor)-α plays a pivotal role in the disruption of macrovascular and microvascular circulation both in vivo and in vitro. AGEs (advanced glycation end-products)/RAGE (receptor for AGEs), LOX-1 [lectin-like oxidized low-density lipoprotein receptor-1) and NF-κB (nuclear factor κB) signalling play key roles in TNF-α expression through an increase in circulating and/or local vascular TNF-α production. The increase in TNF-α expression induces the production of ROS (reactive oxygen species), resulting in endothelial dysfunction in many pathophysiological conditions. Lipid metabolism, dietary supplements and physical activity affect TNF-α expression. The interaction between TNF-α and stem cells is also important in terms of vascular repair or regeneration. Careful scrutiny of these factors may help elucidate the mechanisms that induce vascular dysfunction. The focus of the present review is to summarize recent evidence showing the role of TNF-α in vascular dysfunction in cardiovascular disease. We believe these findings may prompt new directions for targeting inflammation in future therapies.

[1]  J. Falck,et al.  Role of EDHF in type 2 diabetes-induced endothelial dysfunction. , 2008, American journal of physiology. Heart and circulatory physiology.

[2]  A. Armuzzi,et al.  Tumor Necrosis Factor‐α Antagonism Improves Endothelial Dysfunction in Patients With Crohn's Disease , 2008 .

[3]  Guosheng Lin,et al.  TNFR gene-modified mesenchymal stem cells attenuate inflammation and cardiac dysfunction following MI , 2008, Scandinavian cardiovascular journal : SCJ.

[4]  M. Taggart,et al.  TNF-α Alters Nitric Oxide- and Endothelium-Derived Hyperpolarizing Factor-Mediated Vasodilatation in Human Omental Arteries , 2008, Hypertension in pregnancy.

[5]  G. Mancia,et al.  Inflammatory Activation During Coronary Artery Surgery and Its Dose-Dependent Modulation by Statin/ACE-Inhibitor Combination , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[6]  T. Hibi,et al.  Butter feeding enhances TNF‐α production from macrophages and lymphocyte adherence in murine small intestinal microvessels , 2007, Journal of gastroenterology and hepatology.

[7]  S. Felix,et al.  Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells. , 2007, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.

[8]  B. Sepodes,et al.  Exercise training is associated with improved levels of C-reactive protein and adiponectin in ZDF (type 2) diabetic rats. , 2007, Medical science monitor : international medical journal of experimental and clinical research.

[9]  D. Eichler,et al.  Tumor necrosis factor-α reduces argininosuccinate synthase expression and nitric oxide production in aortic endothelial cells , 2007 .

[10]  Brian K. McFarlin,et al.  State of the Art Reviews: The Anti-Inflammatory Actions of Exercise Training , 2007 .

[11]  Laura Herrero,et al.  Obesity, inflammation, and insulin resistance. , 2007, Gastroenterology.

[12]  D. Giugliano,et al.  Effect of a single high-fat meal on endothelial function in patients with the metabolic syndrome: role of tumor necrosis factor-alpha. , 2007, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[13]  T. Collins,et al.  Regulation of NF-κB-dependent Gene Expression by the POU Domain Transcription Factor Oct-1* , 2007, Journal of Biological Chemistry.

[14]  M. Isobe,et al.  Endothelial E-Selectin Potentiates Neovascularization via Endothelial Progenitor Cell–Dependent and –Independent Mechanisms , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[15]  D. Goukassian,et al.  Neovascularization Receptor P75 Is Required in Ischemia-induced Α Tumor Necrosis Factor- Tumor Necrosis Factor-␣ Receptor P75 Is Required in Ischemia-induced Neovascularization , 2007 .

[16]  N. Tewari-Singh,et al.  Tumor Necrosis Factor-α Induces Endothelial Dysfunction in Leprdb Mice , 2007 .

[17]  Z. Ungvari,et al.  Vasculoprotective effects of anti-tumor necrosis factor-alpha treatment in aging. , 2007, The American journal of pathology.

[18]  B. McFarlin,et al.  The Anti-Inflammatory Actions of Exercise Training. , 2007, American journal of lifestyle medicine.

[19]  J. Papadakis,et al.  Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. , 2006, The Journal of rheumatology.

[20]  J. Ouyang,et al.  N-acetylcysteine attenuates TNF-alpha-induced human vascular endothelial cell apoptosis and restores eNOS expression. , 2006, European journal of pharmacology.

[21]  G. Ferraccioli,et al.  Intravascular tumor necrosis factor α blockade reverses endothelial dysfunction in rheumatoid arthritis , 2006, Clinical pharmacology and therapeutics.

[22]  P. Vanhoutte,et al.  Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). , 2006, American journal of physiology. Heart and circulatory physiology.

[23]  A. Koller,et al.  Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE , 2006, European journal of heart failure.

[24]  M. Focardi,et al.  Tumor Necrosis Factor- (cid:1) Induces Endothelial Dysfunction in the Prediabetic Metabolic Syndrome , 2022 .

[25]  T. Rabelink,et al.  TNF-α induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-γ agonist pioglitazone , 2006 .

[26]  D. Green,et al.  Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis , 2006, Rheumatology International.

[27]  M. Gonzalez-gay,et al.  Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. , 2006, Clinical and experimental rheumatology.

[28]  S. Davidge,et al.  Age-associated impairment in vasorelaxation to fluid shear stress in the female vasculature is improved by TNF-alpha antagonism. , 2006, American journal of physiology. Heart and circulatory physiology.

[29]  P. Vardas,et al.  Early Effects of Simvastatin versus Atorvastatin on Oxidative Stress and Proinflammatory Cytokines in Hyperlipidemic Subjects , 2006, Angiology.

[30]  D. Newby,et al.  Vascular and fibrinolytic effects of intra-arterial tumour necrosis factor-alpha in patients with coronary heart disease. , 2006, Clinical science.

[31]  H. Billert,et al.  Regulation of eNOS expression in HCAEC cell line treated with opioids and proinflammatory cytokines. , 2006, Kardiologia polska.

[32]  S. Lerakis,et al.  Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. , 2006, Journal of the American College of Cardiology.

[33]  E. Clementi,et al.  Endothelial Nitric Oxide Synthase Activation by Tumor Necrosis Factor α Through Neutral Sphingomyelinase 2, Sphingosine Kinase 1, and Sphingosine 1 Phosphate Receptors: A Novel Pathway Relevant to the Pathophysiology of Endothelium , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[34]  P. Vanhoutte,et al.  Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). , 2006, American journal of physiology. Heart and circulatory physiology.

[35]  L. Kuo,et al.  TNF-&agr; Contributes to Endothelial Dysfunction in Ischemia/Reperfusion Injury , 2005 .

[36]  C. Stefanadis,et al.  Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure , 2005, European journal of heart failure.

[37]  C. Tıkız,et al.  Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. , 2005, The Journal of rheumatology.

[38]  Helle Bruunsgaard,et al.  Physical activity and modulation of systemic low‐level inflammation , 2005, Journal of leukocyte biology.

[39]  A. Vaag,et al.  Metabolic and Vascular Effects of Tumor Necrosis Factor-α Blockade with Etanercept in Obese Patients with Type 2 Diabetes , 2005, Journal of Vascular Research.

[40]  Robert Krysiak,et al.  Monocyte Release of Tumor Necrosis Factor-α and Interleukin-1β in Primary Type IIa and IIb Dyslipidemic Patients Treated With Statins or Fibrates , 2005, Journal of cardiovascular pharmacology.

[41]  Shao-cai Hong,et al.  Effect of Atorvastatin on Tumor Necrosis Factor α Serum Concentration and mRNA Expression of Adipose in Hypercholesterolemic Rabbits , 2005, Journal of cardiovascular pharmacology.

[42]  S. Fitzgerald,et al.  ROLE OF ENDOTHELIUM‐DERIVED HYPERPOLARIZING FACTOR IN ENDOTHELIAL DYSFUNCTION DURING DIABETES , 2005, Clinical and experimental pharmacology & physiology.

[43]  Toby Lawrence,et al.  IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation , 2005, Nature.

[44]  W. Zou,et al.  TNF‐α expression is transcriptionally regulated by RANK ligand , 2005 .

[45]  B. Dijkmans,et al.  Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.

[46]  Lei Feng,et al.  Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-PCR analysis. , 2005, Diabetes care.

[47]  G. Mancia,et al.  Acute Effect of High-Fat Meal on Endothelial Function in Moderately Dyslipidemic Subjects , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[48]  M. Netea,et al.  Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[49]  S. James,et al.  OF THE BIOCHEMICAL SOCIETY , 2005 .

[50]  J. Ramires,et al.  Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. , 2004, Atherosclerosis.

[51]  B. Aronow,et al.  Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB:p52 dimers , 2004 .

[52]  R. Ferrari,et al.  CD34+ and Endothelial Progenitor Cells in Patients With Various Degrees of Congestive Heart Failure , 2004, Circulation.

[53]  B. Pedersen,et al.  Exercise normalises overexpression of TNF-α in knockout mice , 2004 .

[54]  M. Muc-Wierzgoń,et al.  Simvastatin decreases concentration of interleukin-2 in hypercholesterolemic patients after treatment for 12 weeks. , 2004, Journal of biological regulators and homeostatic agents.

[55]  Bharat B. Aggarwal,et al.  Nuclear factor-κB: its role in health and disease , 2004, Journal of Molecular Medicine.

[56]  K. Koh,et al.  Vascular effects of diet and statin in hypercholesterolemic patients. , 2004, International journal of cardiology.

[57]  Paul M. Ridker,et al.  Inflammation as a Cardiovascular Risk Factor , 2004, Circulation.

[58]  D. Eichler,et al.  Argininosuccinate Synthase Expression Is Required to Maintain Nitric Oxide Production and Cell Viability in Aortic Endothelial Cells* , 2004, Journal of Biological Chemistry.

[59]  J. McMurray,et al.  Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.

[60]  Z. Ungvari,et al.  Proinflammatory phenotype of coronary arteries promotes endothelial apoptosis in aging. , 2004, Physiological genomics.

[61]  U. Das Anti-inflammatory nature of exercise. , 2004, Nutrition.

[62]  L. Khaodhiar,et al.  The effects of atorvastatin on endothelial function in diabetic patients and subjects at risk for type 2 diabetes. , 2004, The Journal of clinical endocrinology and metabolism.

[63]  I. Wilkinson,et al.  Infliximab Improves Endothelial Dysfunction in Systemic Vasculitis: A Model of Vascular Inflammation , 2004, Circulation.

[64]  R. Ferrari,et al.  CD 34 and Endothelial Progenitor Cells in Patients With Various Degrees of Congestive Heart Failure , 2004 .

[65]  Jian-er Tang,et al.  Cardiomyocytes overexpressing TNF‐α attract migration of embryonic stem cells via activation of p38 and c‐Jun amino‐terminal kinase , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[66]  A. Lavoinne,et al.  Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle. , 2003, European journal of biochemistry.

[67]  R. Wimalasundera,et al.  Effect of tumour necrosis factor‐α and interleukin 1β on endothelium‐dependent relaxation in rat mesenteric resistance arteries in vitro , 2003 .

[68]  D. Newby,et al.  Intra-Arterial Tumor Necrosis Factor-&agr; Impairs Endothelium-Dependent Vasodilatation and Stimulates Local Tissue Plasminogen Activator Release in Humans , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[69]  Liying Wang,et al.  Inhibition of TNF-alpha gene expression and bioactivity by site-specific transcription factor-binding oligonucleotides. , 2003, American journal of physiology. Lung cellular and molecular physiology.

[70]  E. Cauza,et al.  Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. , 2002, Wiener klinische Wochenschrift.

[71]  F. Ruschitzka,et al.  Anti–Tumor Necrosis Factor-α Treatment Improves Endothelial Function in Patients With Rheumatoid Arthritis , 2002 .

[72]  D. Sorescu,et al.  Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. , 2002, Congestive heart failure.

[73]  J. Loscalzo,et al.  Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis. , 2002, Vascular pharmacology.

[74]  R. Alexander,et al.  Role of Isoprenylcysteine Carboxyl Methyltransferase in Tumor Necrosis Factor-&agr; Stimulation of Expression of Vascular Cell Adhesion Molecule-1 in Endothelial Cells , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[75]  K. Channon,et al.  Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus: Role of NAD(P)H Oxidase and Endothelial Nitric Oxide Synthase , 2002, Circulation.

[76]  G. Paolisso,et al.  Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. , 2002, Journal of the American College of Cardiology.

[77]  P. Iversen,et al.  Decreased hematopoiesis in bone marrow of mice with congestive heart failure. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[78]  S. Fichtlscherer,et al.  Tumor Necrosis Factor Antagonism With Etanercept Improves Systemic Endothelial Vasoreactivity in Patients With Advanced Heart Failure , 2001, Circulation.

[79]  P. Stenvinkel Endothelial dysfunction and inflammation-is there a link? , 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[80]  M. Shichiri,et al.  Coinduction of endothelial nitric oxide synthase and arginine recycling enzymes in aorta of diabetic rats. , 2001, Nitric oxide : biology and chemistry.

[81]  M. Toborek,et al.  High-Energy Diets, Fatty Acids and Endothelial Cell Function: Implications for Atherosclerosis , 2001, Journal of the American College of Nutrition.

[82]  D. Harrison,et al.  Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. , 2000, Circulation research.

[83]  R. Hofer-Warbinek,et al.  The Transcription Factor NF-κB and the Regulation of Vascular Cell Function , 2000 .

[84]  N. Arakawa,et al.  Effects of tumor necrosis factor-alpha on basal and stimulated endothelium-dependent vasomotion in human resistance vessel. , 2000, Journal of cardiovascular pharmacology.

[85]  A. Ma,et al.  Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. , 2000, Science.

[86]  M. Schroll,et al.  Ageing, tumour necrosis factor‐alpha (TNF‐α) and atherosclerosis , 2000, Clinical and experimental immunology.

[87]  J. van de Voorde,et al.  Endothelial dysfunction in diabetes , 2000, British journal of pharmacology.

[88]  Hiroshi Yamamoto,et al.  The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[89]  K. Channon,et al.  Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. , 2000, Circulation research.

[90]  G. Rimbach,et al.  Macrophages Stimulated with IFN-γ Activate NF-κB and Induce MCP-1 Gene Expression in Primary Human Endothelial Cells , 2000 .

[91]  D. Sorescu,et al.  NAD(P)H oxidase: role in cardiovascular biology and disease. , 2000, Circulation research.

[92]  Y. Hattori,et al.  The preferred source of arginine for high-output nitric oxide synthesis in blood vessels. , 2000, Seminars in perinatology.

[93]  Frede,et al.  Tumor Necrosis Factor-a ( TNF-a ) Potently Enhances In Vitro Macrophage Production From Primitive Murine Hematopoietic Progenitor Cells in Combination With Stem Cell Factor and Interleukin-7 : Novel Stimulatory Role of p 55 TNF Receptors , 2000 .

[94]  Y. Hayashi,et al.  Expression of NADH/NADPH oxidase p22phox in human coronary arteries. , 1999, Circulation.

[95]  N. Olashaw,et al.  TNF-α-Induced Growth Suppression of CD34+ Myeloid Leukemic Cell Lines Signals Through TNF Receptor Type I and Is Associated with NF-κB Activation , 1999, The Journal of Immunology.

[96]  D. Harrison,et al.  Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. , 1999, Circulation.

[97]  R. Busse,et al.  Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. , 1999, Circulation.

[98]  J. Connell,et al.  Insulin-mediated vasodilation and glucose uptake are functionally linked in humans. , 1999, Hypertension.

[99]  K. Pritchard,et al.  Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[100]  A. Hamsten,et al.  Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. , 1998, Metabolism: clinical and experimental.

[101]  M. Merika,et al.  Distinct functional properties of IkappaB alpha and IkappaB beta , 1997, Molecular and cellular biology.

[102]  N. Mackman,et al.  Lipopolysaccharide Induction of the Tumor Necrosis Factor-α Promoter in Human Monocytic Cells , 1997, The Journal of Biological Chemistry.

[103]  S. Jacobsen,et al.  Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+ CD38-) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3, and inhibitory effects of TGF-beta and TNF-alpha. , 1997, Journal of immunology.

[104]  E. Block,et al.  Proinflammatory cytokines downregulate gene expression and activity of constitutive nitric oxide synthase in porcine pulmonary artery endothelial cells. , 1997, Research communications in molecular pathology and pharmacology.

[105]  A. Allison,et al.  Inhibitory effect of di-catechol rooperol on VCAM-1 and iNOS expression in cytokine-stimulated endothelium. , 1996, Life sciences.

[106]  M. Ushio-Fukai,et al.  p22phox Is a Critical Component of the Superoxide-generating NADH/NADPH Oxidase System and Regulates Angiotensin IIinduced Hypertrophy in Vascular Smooth Muscle Cells* , 1996, The Journal of Biological Chemistry.

[107]  L. Owen-Schaub,et al.  Human Tumor Necrosis Factor Receptor p75/80 (CD120b) Gene Structure and Promoter Characterization* , 1996, The Journal of Biological Chemistry.

[108]  J A Thompson,et al.  Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[109]  A. Baron,et al.  Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. , 1996, The Journal of clinical investigation.

[110]  D. Harrison,et al.  Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. , 1996, The Journal of clinical investigation.

[111]  K. Pritchard,et al.  Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. , 1995, Circulation research.

[112]  A. Tedgui,et al.  Increased production of tumor necrosis factor and interleukin-6 by arterial wall of aged rats. , 1995, The American journal of physiology.

[113]  K. Feingold,et al.  Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[114]  S. Jacobsen,et al.  Tumor necrosis factor-alpha (TNF-alpha) potently enhances in vitro macrophage production from primitive murine hematopoietic progenitor cells in combination with stem cell factor and interleukin-7: novel stimulatory role of p55 TNF receptors. , 1994, Blood.

[115]  E. Smeland,et al.  Tumor Necrosis Factor-a Inhibits Stem Cell Factor-induced Proliferation of Human Bone Marrow Progenitor Cells In Vitro Role of p55 and p75 Tumor Necrosis Factor Receptors , 2022 .

[116]  Y. Hattori,et al.  Argininosuccinate synthetase mRNA and activity are induced by immunostimulants in vascular smooth muscle. Role in the regeneration or arginine for nitric oxide synthesis. , 1994, The Journal of biological chemistry.

[117]  K. Macnaul,et al.  Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. , 1993, Biochemical and Biophysical Research Communications - BBRC.

[118]  M. Yoshizumi,et al.  Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. , 1993, Circulation research.

[119]  K. Feingold,et al.  Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. , 1993, Endocrinology.

[120]  J. Kolls,et al.  Tumor necrosis factor-alpha inhibits endothelium-dependent relaxation. , 1993, Journal of applied physiology.

[121]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[122]  J. Downey,et al.  Superoxide dismutase therapy for myocardial ischemia. , 1991, Free radical research communications.

[123]  Y. Shimada,et al.  Tumor necrosis factor reduces lifespan of human endothelial cells in vitro , 1990, Mechanisms of Ageing and Development.

[124]  A. M. Lefer,et al.  Anti-EDRF effect of tumor necrosis factor in isolated, perfused cat carotid arteries. , 1989, The American journal of physiology.

[125]  H. Koeffler,et al.  Recombinant human TNF induces production of granulocyte–monocyte colony-stimulating factor , 1986, Nature.

[126]  A. Guyton,et al.  Human Physiology and Mechanisms of Disease , 1982 .